> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Axsome NDA Filed for Migraine Therapy
- URL: https://www.fdaweb.com/axsome-nda-filed-for-migraine-therapy/
- Published: 2021-09-14T12:00:00.000Z
- Updated: 2026-09-14T17:14:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150135

FDA has accepted for review an Axsome Therapeutics NDA for AXS-07 (meloxicam-rizatriptan) for the acute treatment of migraine. The submission is supported by data from two Phase 3 randomized, double-blind, controlled trials, MOMENTUM and INTERCEPT, which the company says demonstrated statistically significant elimination of migraine pain compared to placebo and active controls. The agency has set a user fee review action target date of 4/30/2022.

Axsome describes AXS-07 as an oral, rapidly absorbed, multi-mechanistic drug comprising meloxicam and rizatriptan. Meloxicam is a COX-2 preferential non-steroidal anti-inflammatory drug that is enabled by Axsome’s Molecular Solubility Enhanced Inclusion Complex technology to allow rapid absorption while maintaining a long plasma half-life, the company says. Rizatriptan belongs to the triptan drug class and has been used for many years in treating migraines.